Searchable abstracts of presentations at key conferences in endocrinology

ea0081ep7 | Adrenal and Cardiovascular Endocrinology | ECE2022

A phase III trial of recombinant human growth hormone in pediatric patients with growth failure caused by chronic kidney disease

Xu Hong , Tang Xiaoshan , Shen Qian , Chen Jing , Fang Xiaoyan , Zhang Aihua , Zhao Fei , Chen Qiuxia , Huang Wenyan , Wang Ping , Sun Liwen , Xiao Huijie , Xu Ke , Liu Xiaorong , Chen Zhi , Chen Chaoying , Tu Juan , Wu Yubing , Wang Xiuli , Mao Jianhua , Lu Zhihong , Wang Jingjing , Nie Xiaojing , Yu Zihua , Huang Jun , Liu Cuihua , Cao Guanghai , Li Yufeng , Zhu Yaju , Zhang Jianjiang , Wang Miao , Wang Mo , Yang Haiping

Background and objective: Children with chronic kidney disease (CKD) have impaired growth that leads to short stature in adulthood and treatment with recombinant human growth hormone (rhGH) is associated with improved growth. This study aimed to evaluate the efficacy and safety of daily rhGH (Jintropin®) in children in China with growth failure caused by CKD prior to transplantation.Methods: Prepubertal patients (2–13 years old) with CKD-relate...